PMID- 31725459
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20200413
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 132
IP  - 22
DP  - 2019 Nov 20
TI  - Unsatisfying antiviral therapeutic effect in patients with mother-to-child 
      transmissed chronic hepatitis B virus infection: a prospective multi-center 
      clinical study.
PG  - 2647-2656
LID - 10.1097/CM9.0000000000000522 [doi]
AB  - BACKGROUND: Few data are available regarding the progression of liver disease and 
      therapeutic efficacy in chronic hepatitis B virus (HBV) carriers infected by 
      mother-to-child transmission (MTCT). This study aimed to investigate these two 
      aspects by comparing the adult chronic HBV carriers in MTCT group with those in 
      horizontal transmission group. METHODS: The 683 adult chronic HBV patients 
      qualified for liver biopsy including 191 with MTCT and 492 with horizontal 
      transmission entered the multi-center prospective study from October 2013 to May 
      2016. Biopsy results from 217 patients at baseline and 78 weeks post antiviral 
      therapy were collected. RESULTS: Patients infected by MTCT were more likely to 
      have e antigen positive (68.6% vs. 58.2%, chi = -2.491, P = 0.012) than those with 
      horizontal transmission. However, in patients with MTCT, levels of alkaline 
      phosphatase (ALP) (P = 0.031), Fibroscan (P = 0.013), N-terminal propeptide of 
      Type III procollagen (PIIINP) (P = 0.014), and Laminin (LN) (P = 0.006) were 
      high, in contrast to the patients with horizontal transmission for whom the 
      levels of albumin (ALB) (P = 0.041), matrix metalloproteinase-3 (MMP-3) 
      (P = 0.001) were high. The 47.2% of patients with MTCT and 36.8% of those with 
      horizontal transmission had significant liver fibrosis (P = 0.013). Following 
      antiviral therapy for 78 weeks, 21.2% and 38.0% patients with MTCT and horizontal 
      transmission acquired hepatitis B e antigen (HBeAg) clearance, respectively 
      (P = 0.043), and the virological response rates were 54.7% and 74.1% in the MTCT 
      and horizontal groups, respectively (P = 0.005). MTCT was a risk factor for HBeAg 
      clearance and virological response. CONCLUSION: Adult patients with MTCT were 
      more prone to severe liver diseases, and the therapeutic efficacy was relatively 
      poor, which underlined the importance of earlier, long-term treatment and 
      interrupting perinatal transmission. TRIAL REGISTRATION: NCT01962155; 
      https://clinicaltrials.gov.
FAU - Li, Jun
AU  - Li J
AD  - Department of Infectious Diseases, Center for Liver Disease, Peking University 
      First Hospital, Beijing 100034, China.
FAU - Dong, Xiao-Qin
AU  - Dong XQ
AD  - Department of Infectious Diseases, Tongji Hospital of Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
FAU - Wu, Zhao
AU  - Wu Z
AD  - Department of Infectious Diseases, Center for Liver Disease, Peking University 
      First Hospital, Beijing 100034, China.
FAU - Ma, An-Lin
AU  - Ma AL
AD  - Department of Infectious Diseases, China-Japan Friendship Hospital, Beijing 
      100029, China.
FAU - Xie, Shi-Bin
AU  - Xie SB
AD  - Department of Infectious Diseases, The Third Affiliated Hospital Sun Yat-Sen 
      University, Guangzhou, Guangdong 510000, China.
FAU - Zhang, Xu-Qing
AU  - Zhang XQ
AD  - Department of Infectious Diseases, South West Hospital Affiliated to Third 
      Military Medical University, Chongqing 400038, China.
FAU - Zhang, Zhan-Qing
AU  - Zhang ZQ
AD  - Department of Hepatology, Shanghai Public Health Clinical Center, Fudan 
      University, Shanghai 200083, China.
FAU - Zhang, Da-Zhi
AU  - Zhang DZ
AD  - Department of Infectious Diseases, Second Affiliated Hospital of Chongqing 
      Medical University, Chongqing 404000, China.
FAU - Zhao, Wei-Feng
AU  - Zhao WF
AD  - Department of Infectious Diseases, Xinxiang Medical University Third Hospital, 
      Xinxiang, Henan 453003, China.
FAU - Zhang, Guo
AU  - Zhang G
AD  - Department of Infectious Diseases, The People's Hospital of Guangxi Zhuang 
      Autonomous Region, Nanning, Guangxi 530021, China.
FAU - Cheng, Jun
AU  - Cheng J
AD  - Department of Infectious Diseases, Di Tan Hospital Affiliated to Capital Medical 
      University, Beijing 100015, China.
FAU - Xie, Qing
AU  - Xie Q
AD  - Department of Infectious Diseases, Rui Jin Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 200090, China.
FAU - Li, Jun
AU  - Li J
AD  - Department of Infectious Diseases, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, Jiangsu 211166, China.
FAU - Zou, Zhi-Qiang
AU  - Zou ZQ
AD  - Department of Infectious Diseases, Yantai City Hospital for Infectious Disease, 
      Yantai, Shandong 264001, China.
FAU - Liu, Ying-Xia
AU  - Liu YX
AD  - Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of 
      Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518034, 
      China.
FAU - Wang, Gui-Qiang
AU  - Wang GQ
AD  - Department of Infectious Diseases, Center for Liver Disease, Peking University 
      First Hospital, Beijing 100034, China.
AD  - The Collaborative Innovation Center for Diagnosis and Treatment of Infectious 
      Diseases, Zhejiang University, Hangzhou, Zhejiang 310085, China.
AD  - Department of Infectious Diseases, Peking University International Hospital, 
      Beijing 102206, China.
FAU - Zhao, Hong
AU  - Zhao H
AD  - Department of Infectious Diseases, Center for Liver Disease, Peking University 
      First Hospital, Beijing 100034, China.
AD  - Department of Infectious Diseases, Peking University International Hospital, 
      Beijing 102206, China.
CN  - China Hepatitis B Related Fibrosis Assessment Research Group
LA  - eng
SI  - ClinicalTrials.gov/NCT01962155
PT  - Journal Article
PT  - Multicenter Study
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Hepatitis B e Antigens)
RN  - 0 (Laminin)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
SB  - IM
MH  - Adult
MH  - Alkaline Phosphatase/metabolism
MH  - Female
MH  - Hepatitis B e Antigens/metabolism
MH  - Hepatitis B, Chronic/immunology/metabolism/*prevention & control
MH  - Humans
MH  - Infectious Disease Transmission, Vertical/*prevention & control
MH  - Laminin/metabolism
MH  - Liver/drug effects/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
PMC - PMC6940093
EDAT- 2019/11/15 06:00
MHDA- 2020/04/14 06:00
PMCR- 2019/11/20
CRDT- 2019/11/15 06:00
PHST- 2019/11/15 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
PHST- 2019/11/15 06:00 [entrez]
PHST- 2019/11/20 00:00 [pmc-release]
AID - CMJ-2019-784 [pii]
AID - 10.1097/CM9.0000000000000522 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2019 Nov 20;132(22):2647-2656. doi: 
      10.1097/CM9.0000000000000522.